Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Sanofi”

Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CVCompleted
NCT01190228Phase 3Updated Mar 28, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Japanese Encephalitis · Varicella
Philippines
Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 YearsCompleted
NCT02550197Phase 3Updated Mar 28, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza
South Korea
Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409Completed
NCT02255656Phase 4Updated Mar 28, 2022
Sponsor: Genzyme, a Sanofi Company
Relapsing Remitting Multiple Sclerosis
United States, Argentina, Australia, Belgium, Brazil +14 more
Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy ToddlersCompleted
NCT01436396Phase 3Updated Mar 25, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Dengue · Dengue Hemorrhagic Fever · Yellow Fever
Colombia, Peru
Randomized Study of the Efficacy and Safety of a Single Dose of Synvisc-One® in Chinese Patients With Symptomatic Osteoarthritis of the KneeCompleted
NCT03190369Phase 3Updated Mar 25, 2022
Sponsor: Genzyme, a Sanofi Company
Osteoarthritis
China
Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy SubjectsTerminated
NCT02992418Phase 3Updated Mar 25, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Dengue Fever · Dengue Hemorrhagic Fever
Philippines
Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in MalaysiaCompleted
NCT01254422Phase 3Updated Mar 25, 2022
Sponsor: Sanofi
Dengue Fever · Dengue Hemorrhagic Fever
Malaysia
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®Completed
NCT02979535Phase 3Updated Mar 25, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Dengue Fever · Dengue Hemorrhagic Fever · Human Papillomavirus Disease
Mexico
Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes MellitusCompleted
NCT02735044Phase 3Updated Mar 25, 2022
Sponsor: Sanofi
Type 1 Diabetes Mellitus
United States, Argentina, Brazil, Bulgaria, Canada +19 more
Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy ToddlersCompleted
NCT01411241Phase 3Updated Mar 25, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Dengue · Dengue Hemorrhagic Fever
Mexico
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime InsulinCompleted
NCT01499082Phase 3Updated Mar 25, 2022
Sponsor: Sanofi
Type 2 Diabetes Mellitus
United States, Canada, Czechia, Estonia, Finland +8 more
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®Completed
NCT02993757Phase 3Updated Mar 25, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Dengue Fever · Dengue Hemorrhagic Fever · Human Papillomavirus Disease
Malaysia
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension PeriodCompleted
NCT02787551Phase 3Updated Mar 25, 2022
Sponsor: Sanofi
Type 2 Diabetes Mellitus
United States, Canada, Estonia, Germany, Israel +4 more
Evaluation of Renvela in Patients With Chronic Kidney Disease Not On Dialysis And Hyperphosphatemia In ChinaCompleted
NCT03001011Phase 3Updated Mar 25, 2022
Sponsor: Sanofi
Hyperphosphatemia
China
Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia BCompleted
NCT02234310Phase 3Updated Mar 25, 2022
Sponsor: Bioverativ, a Sanofi company
Hemophilia B
United States, Australia, Denmark, France, Ireland +6 more
A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS)Completed
NCT00531232Phase 2Updated Mar 24, 2022
Sponsor: Genzyme, a Sanofi Company
Myelodysplastic Syndromes · Secondary Acute Myeloid Leukemia (AML)
United States
Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever VaccineCompleted
NCT01488890Phase 2Updated Mar 24, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Dengue · Dengue Fever · Dengue Hemorrhagic Fever · Yellow Fever
United States
Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin AmericaCompleted
NCT00993447Phase 2Updated Mar 24, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Dengue · Dengue Hemorrhagic Fever · Dengue Virus · Dengue Fever
Colombia, Honduras, Mexico, Puerto Rico
Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue VaccineCompleted
NCT01943825Phase 2Updated Mar 24, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Dengue · Dengue Fever · Dengue Hemorrhagic Fever
United States
Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose ScheduleCompleted
NCT02623725Phase 2Updated Mar 24, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Dengue Fever · Dengue Hemorrhagic Fever
Brazil, Colombia, Honduras, Mexico, Puerto Rico
A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCITerminated
NCT03236311Phase 2Updated Mar 24, 2022
Sponsor: Sanofi
Microvascular Coronary Artery Disease
United States, Denmark, Netherlands, South Korea, Sweden
Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary FibrosisCompleted
NCT02345070Phase 2Updated Mar 24, 2022
Sponsor: Sanofi
Idiopathic Pulmonary Fibrosis
United States, Argentina, Australia, Canada, Chile +14 more
A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes MellitusCompleted
NCT02973321Phase 2Updated Mar 24, 2022
Sponsor: Sanofi
Type 2 Diabetes Mellitus
United States, Canada, Czechia, Germany, Hungary +3 more
To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine and Artefenomel in Adults and Children With Uncomplicated Plasmodium Falciparum MalariaTerminated
NCT02497612Phase 2Updated Mar 24, 2022
Sponsor: Sanofi
Plasmodium Falciparum Infection
Benin, Burkina Faso, Gabon, Kenya, Mozambique +2 more
Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of AgeCompleted
NCT02628444Phase 2Updated Mar 24, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Dengue Fever · Dengue Hemorrhagic Fever
Colombia, Philippines

Previous page Next page